menu search

ADGI / Why Adagio Therapeutics Stock Is Soaring Today

Why Adagio Therapeutics Stock Is Soaring Today
Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment. Read More
Posted: Mar 30 2022, 10:23
Author Name: Benzinga
Views: 110818

ADGI News  

Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%

By 24/7 Wall Street
August 22, 2022

Hedge Fund M28 Capital Increases Adagio Therapeutics (ADGI) Stake to 8.5%

Last Friday, health care focused hedge fund M28 Capital filed a 13D/A with the US Securities & Exchange Committee revealing it bought 2.85 million Ad more_horizontal

Why Adagio Therapeutics Stock Is Soaring Today

By Benzinga
March 30, 2022

Why Adagio Therapeutics Stock Is Soaring Today

Adagio Therapeutics Inc (NASDAQ: ADGI) is trading higher Wednesday after the company announced its investigational drug adintrevimab (ADG20) was the more_horizontal

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

By Seeking Alpha
February 16, 2022

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron. more_horizontal

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

By Seeking Alpha
February 16, 2022

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron. more_horizontal

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

By Seeking Alpha
February 16, 2022

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Three recent independent in-vitro studies show that ADG20 has neutralization activity against Omicron. more_horizontal

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

By The Motley Fool
January 20, 2022

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19. more_horizontal

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

By The Motley Fool
January 20, 2022

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19. more_horizontal

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

By The Motley Fool
January 20, 2022

Why Shares of Adagio Therapeutics Soared 25.9% on Thursday

The clinical-stage biotech company is working on an antiviral treatment to fight multiple variants of COVID-19. more_horizontal


Search within

Pages Search Results: